A successful portfolio strategy sets direction for the future and maximises value. We will help you to plan the strategic management of your product portfolio, enabling you to make the right investment decisions, optimise value, and allocate the most profitable use of resources.
56a6.jpg)
Strategic pricing is essential to maximising revenue and achieving long-term organisational results. Our market insights will help to develop pricing and reimbursement strategies that reflect, maintain, and enhance the value of your assets over their lifetime.
A comprehensive landscape assessment is vital for identifying the access opportunities and challenges for your product. We will assess the current and future treatment, pricing, and reimbursement landscape to ensure that your market access strategies are underpinned by high-value insights.
We test and develop target product profiles with experts payers and KOLs to assess their market access potential. We use their feedback on the perceived value of your product to identify evidence gaps, provide guidance on minimum thresholds to achieve reimbursement and input into future development plans.
Innovative engagement approaches are invaluable for improving payer relationships. We will develop a range of payer engagement programmes including expert panels, advisory boards, mock negotiations and training sessions to ensure closer proximity with payers and establish long-term trust-based relationships.
We conduct payer research in over 50 mature and emerging markets including Brazil, India and China to help you maximise your competitive advantage in the markets offering the best opportunities for growth.
Keeping up with the Coronavirus: Monitoring the impact of COVID-19 on the market access landscape.
How will COVID-19 affect the financing of healthcare provision across the US?
Selected deals for SARS-CoV-2 vaccines in late stage development.
If you have any further questions or wish to find out more about any of the content on this page click on the button below:
Director, Market Access
Rachel Howard is a Director in our London office. With over 12 years’ experience working in life sciences, Rachel has extensive experience managing large scale, complex studies, both qualitative and quantitative. Over the course of her career Rachel has lived and worked in London, New York and Singapore, giving her broad global experience spanning three continents and particular emerging markets experience. Rachel has a University Diploma in European Market Access (EMAUD) and focuses on market access and pricing research, with a particular focus on vaccines and infectious diseases. In 2020, she led a multi-client study interviewing over 70 payers, NITAGs and KOLs spanning 8 global markets to evaluate the impact of COVID-19 on market access, and has published a number of thought pieces in this area.
UK Office
